Metabolic Alterations as Biomarkers in Gastrointestinal Tract Cancers

Overview

This editorial summarizes recent advances highlighting the role of altered metabolic and inflammatory markers as prognostic and diagnostic tools in gastrointestinal cancers including colorectal, gastric, and pancreatic malignancies. Key metabolic indices such as the system immune-inflammation index (SII) and triglyceride-glucose (TyG) index have emerged as significant predictors of disease progression and patient outcomes.

Background

Gastrointestinal tract cancers such as gastric cancer, pancreatic ductal adenocarcinoma, and colorectal cancer remain leading causes of cancer-related mortality worldwide. Tumor progression and prognosis are influenced not only by genetic alterations but also by the tumor microenvironment, systemic inflammation, and metabolic dysregulation. Identifying reliable biomarkers that integrate inflammatory, nutritional, and metabolic parameters is critical for improving early diagnosis, risk stratification, and therapeutic decision-making in these aggressive cancers.

Data Highlights

Key Findings

• System immune-inflammation index (SII) is a robust prognostic marker predicting poor survival in colorectal cancer.
• Combining inflammatory and nutritional indices (CEA, SII, PNI) enhances diagnostic accuracy for lymph node metastasis in gastric cancer.
• Triglyceride-glucose (TyG) index is linked to colorectal cancer risk and serves as a low-cost screening tool for high-risk individuals.
• In pancreatic cancer, a lower TyG index reflects a metabolic shift associated with liver metastasis and cachexia, indicating its role as a reverse prognostic biomarker.
• Remnant cholesterol levels correlate with tumor aggressiveness in pancreatic neuroendocrine tumors, suggesting lipid metabolism dysregulation.
• Tumor microenvironment factors such as TGF-β and somatostatin signaling pathways contribute to tumor heterogeneity and therapy resistance.

Clinical Implications

Integrating systemic inflammatory and metabolic biomarkers can improve early detection, prognostication, and personalized treatment strategies in gastrointestinal cancers. The use of composite indices like SII and TyG index offers accessible, cost-effective tools for risk stratification and monitoring. Further prospective, multicenter studies are needed to standardize these biomarkers and translate findings into clinical practice.

Conclusion

Gastrointestinal cancers exhibit complex metabolic and inflammatory alterations that significantly impact tumor progression and patient outcomes. Leveraging these biomarkers holds promise for enhancing diagnostic accuracy and guiding precision oncology approaches in these malignancies.

References

1. Wang and Jiang 2023 -- Prognostic significance of system immune-inflammation index in colorectal cancer
2. Dai et al. 2023 -- Combined biomarkers improve lymph node metastasis diagnosis in gastric cancer
3. Wang et al. 2023 -- Triglyceride-glucose index and colorectal cancer incidence
4. Yi et al. 2023 -- TyG index as a prognostic biomarker in pancreatic cancer liver metastasis
5. Zhou et al. 2023 -- Remnant cholesterol and tumor grade in pancreatic neuroendocrine neoplasms
6. Ungefronen et al. 2023 -- TGF-β and somatostatin signaling in pancreatic adenocarcinoma and neuroendocrine tumors